Head to Head Contrast: Syneron Medical (ELOS) and Its Competitors
Syneron Medical (NASDAQ: ELOS) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its peers? We will compare Syneron Medical to similar companies based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, institutional ownership and dividends.
Valuation and Earnings
This table compares Syneron Medical and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Syneron Medical Competitors||$827.05 million||$159.46 million||34.85|
Syneron Medical’s peers have higher revenue and earnings than Syneron Medical. Syneron Medical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Syneron Medical and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Syneron Medical Competitors||-128.72%||-37.35%||-10.53%|
This is a breakdown of current recommendations and price targets for Syneron Medical and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Syneron Medical Competitors||322||1480||2596||105||2.55|
Syneron Medical presently has a consensus target price of $11.00, suggesting a potential upside of 0.00%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.42%. Given Syneron Medical’s peers stronger consensus rating and higher possible upside, analysts clearly believe Syneron Medical has less favorable growth aspects than its peers.
Risk & Volatility
Syneron Medical has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Syneron Medical’s peers have a beta of 1.08, meaning that their average share price is 8% more volatile than the S&P 500.
Institutional & Insider Ownership
69.2% of Syneron Medical shares are owned by institutional investors. Comparatively, 63.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 12.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Syneron Medical peers beat Syneron Medical on 6 of the 11 factors compared.
About Syneron Medical
Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company’s aesthetic medical products are based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company’s products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, tattoo removal, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and laser-assisted lipolysis.
Receive News & Ratings for Syneron Medical Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneron Medical Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.